/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Our approach is to develop antibiotic candidates with a Gram-positive selective spectrum ( GPSS ) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid ( DNA ) polymerase II…
$1.39
+$0.00 (+0.00%)
EOD Sep 18, 2026
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$8M
▲ +43.5% YoY
Op. Margin
—
ROIC
-100.68%
▲ +1596.5pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$6M
▲ +34.6% YoY
Net Debt
-$11M
Net Cash Position
Cash & Equiv.
$11M
Continue Research
SourceComputed from the 10-Q filed 13 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.